NOVO-VERAMIL TABLET

国: カナダ

言語: 英語

ソース: Health Canada

即購入

製品の特徴 製品の特徴 (SPC)
29-05-2013

有効成分:

VERAPAMIL HYDROCHLORIDE

から入手可能:

TEVA CANADA LIMITED

ATCコード:

C08DA01

INN(国際名):

VERAPAMIL

投薬量:

80MG

医薬品形態:

TABLET

構図:

VERAPAMIL HYDROCHLORIDE 80MG

投与経路:

ORAL

パッケージ内のユニット:

100/500/1000

処方タイプ:

Prescription

治療領域:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0113846002; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2018-05-15

製品の特徴

                                PRODUCT MONOGRAPH
PR
NOVO-VERAMIL
(verapamil hydrochloride)
80 mg, 120 mg tablets
Antiarrhythmic/Antianginal/Antihypertensive Agent
PR
NOVO-VERAMIL SR
(verapamil hydrochloride)
240 mg sustained release tablets
Antihypertensive Agent
Teva Canada Limited
Date of Preparation:
30 Novopharm Court
May 28, 2013
Toronto, Ontario
M1B 2K9
Submission Control No: 164741
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
5
ADVERSE REACTIONS
...............................................................................................................
9
DRUG INTERACTIONS
.............................................................................................................
12
DOSAGE AND ADMINISTRATION
.........................................................................................
18
OVERDOSAGE
...........................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
21
STORAGE AND STABILITY
.....................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 26
PART II: SCIENTIFIC INFORMATION
...............................................................................
28
PHARMACEUTICAL INFORMATION
...................................................................................
                                
                                完全なドキュメントを読む
                                
                            

他の言語のドキュメント

製品の特徴 製品の特徴 フランス語 28-05-2013

この製品に関連するアラートを検索

ドキュメントの履歴を表示する